BioMarin Pharmaceutical Inc (BMRN) stock
BMRNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 8/30104% above fair value
$61.43+2.92 (+4.99%)
Close on Nov 18, 2026Market cap $11.89BP/E 161.7Yield –
BioMarin Pharmaceutical operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
BioMarin Pharmaceutical's operating cash flow for the twelve months ending Jun 30, 2026 was $857.09M, up 11.8% year over year. For fiscal 2025 it was $827.99M, up 44.5% from the year before. The highest annual figure on record is $827.99M in fiscal 2025.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $827.99M | +44.5% |
| FY2024 | Dec 31, 2024 | $572.84M | +259.7% |
| FY2023 | Dec 31, 2023 | $159.26M | -9.5% |
| FY2022 | Dec 31, 2022 | $175.90M | -42.2% |
| FY2021 | Dec 31, 2021 | $304.54M | +256.7% |
| FY2020 | Dec 31, 2020 | $85.37M | +76.9% |
| FY2019 | Dec 31, 2019 | $48.26M | +138.8% |
| FY2018 | Dec 31, 2018 | $20.21M | – |
| FY2017 | Dec 31, 2017 | -$8.76M | – |
| FY2016 | Dec 31, 2016 | -$227.84M | – |
| FY2015 | Dec 31, 2015 | -$219.50M | – |
| FY2014 | Dec 31, 2014 | -$70.42M | – |
| FY2013 | Dec 31, 2013 | -$57.34M | -425.6% |
| FY2012 | Dec 31, 2012 | $17.61M | -4.4% |
| FY2011 | Dec 31, 2011 | $18.42M | -1.8% |
| FY2010 | Dec 31, 2010 | $18.75M | -78.6% |
| FY2009 | Dec 31, 2009 | $87.73M | – |
| FY2008 | Dec 31, 2008 | -$9.18M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $168.11M | -9.3% |
| Q1 FY2026 | Mar 31, 2026 | $220.65M | +26.5% |
| Q4 FY2025 | Dec 31, 2025 | $99.64M | -46.3% |
| Q3 FY2025 | Sep 30, 2025 | $368.69M | +66.5% |
| Q2 FY2025 | Jun 30, 2025 | $185.27M | +56.0% |
| Q1 FY2025 | Mar 31, 2025 | $174.39M | +271.3% |
| Q4 FY2024 | Dec 31, 2024 | $185.63M | +575.4% |
| Q3 FY2024 | Sep 30, 2024 | $221.48M | +63.3% |
| Q2 FY2024 | Jun 30, 2024 | $118.76M | +69.5% |
| Q1 FY2024 | Mar 31, 2024 | $46.97M | – |
| Q4 FY2023 | Dec 31, 2023 | $27.48M | +305.0% |
| Q3 FY2023 | Sep 30, 2023 | $135.65M | -14.3% |
| Q2 FY2023 | Jun 30, 2023 | $70.06M | +24.6% |
| Q1 FY2023 | Mar 31, 2023 | -$73.93M | – |
| Q4 FY2022 | Dec 31, 2022 | $6.79M | -39.3% |
| Q3 FY2022 | Sep 30, 2022 | $158.32M | +63.1% |
| Q2 FY2022 | Jun 30, 2022 | $56.23M | -32.1% |
| Q1 FY2022 | Mar 31, 2022 | -$45.43M | -140.0% |
| Q4 FY2021 | Dec 31, 2021 | $11.18M | – |
| Q3 FY2021 | Sep 30, 2021 | $97.06M | +12.6% |
| Q2 FY2021 | Jun 30, 2021 | $82.78M | +198.5% |
| Q1 FY2021 | Mar 31, 2021 | $113.51M | – |
| Q4 FY2020 | Dec 31, 2020 | -$13.38M | -123.3% |
| Q3 FY2020 | Sep 30, 2020 | $86.21M | +22.9% |
| Q2 FY2020 | Jun 30, 2020 | $27.74M | – |
| Q1 FY2020 | Mar 31, 2020 | -$15.19M | – |
| Q4 FY2019 | Dec 31, 2019 | $57.34M | +16.1% |
| Q3 FY2019 | Sep 30, 2019 | $70.13M | +48.6% |
| Q2 FY2019 | Jun 30, 2019 | -$24.34M | – |
| Q1 FY2019 | Mar 31, 2019 | -$54.87M | – |
| Q4 FY2018 | Dec 31, 2018 | $49.37M | +237.9% |
| Q3 FY2018 | Sep 30, 2018 | $47.20M | +23.3% |
| Q2 FY2018 | Jun 30, 2018 | -$33.86M | -280.3% |
| Q1 FY2018 | Mar 31, 2018 | -$42.51M | – |
| Q4 FY2017 | Dec 31, 2017 | $14.61M | – |
| Q3 FY2017 | Sep 30, 2017 | $38.29M | – |
| Q2 FY2017 | Jun 30, 2017 | $18.78M | – |
| Q1 FY2017 | Mar 31, 2017 | -$80.44M | – |
| Q4 FY2016 | Dec 31, 2016 | -$210.00K | – |
| Q3 FY2016 | Sep 30, 2016 | -$10.37M | – |
See a number that looks wrong?